



## POSTER PRESENTATION

## Open Access

# A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with Systemic Sclerosis in a large European cohort

L Bossini-Castillo<sup>1</sup>, JCA Broen<sup>2</sup>, C P Simeon<sup>3</sup>, L Beretta<sup>4</sup>, M C Vonk<sup>2</sup>, N Ortego-Centeno<sup>5</sup>, G Espinosa<sup>6</sup>, P Carreira<sup>7</sup>, M T Camps<sup>8</sup>, N Navarrete<sup>9</sup>, M F González-Escribano<sup>10</sup>, E Vicente-Rabaneda<sup>11</sup>, L Rodríguez<sup>12</sup>, C Tolosa<sup>13</sup>, J A Román-Ivorra<sup>14</sup>, I Gómez-Gracia<sup>15</sup>, F J García-Hernández<sup>16</sup>, I Castellví<sup>17</sup>, M Gallego<sup>18</sup>, A Fernández-Nebro<sup>19</sup>, M V Egurbide<sup>20</sup>, V Follonosa<sup>3</sup>, P García de la Peña<sup>21</sup>, A Pros<sup>22</sup>, M A González-Gay<sup>23</sup>, R Hesselstrand<sup>24</sup>, G Riemekasten<sup>25</sup>, T Witte<sup>26</sup>, MJH Coenen<sup>27</sup>, B P Koeleman<sup>28</sup>, F Houssiau<sup>29</sup>, V Smith<sup>30</sup>, F De Keyser<sup>30</sup>, R Westhovens<sup>31</sup>, E De Langhe<sup>31</sup>, A E Voskuyl<sup>32</sup>, A J Schuerwegh<sup>33</sup>, M M Chee<sup>34</sup>, R Madhok<sup>34</sup>, P Shiels<sup>34</sup>, C Fonseca<sup>35</sup>, C Denton<sup>35</sup>, K Claes<sup>36</sup>, L Padykov<sup>37</sup>, A Nordin<sup>37</sup>, Ø Palm<sup>38</sup>, B A Lie<sup>39</sup>, P Airó<sup>40</sup>, R Scorza<sup>4</sup>, J M van Laar<sup>41</sup>, N Hunzelmann<sup>42</sup>, A Kreuter<sup>43</sup>, A Herrick<sup>44</sup>, J Worthington<sup>44</sup>, TRDJ Radstake<sup>2</sup>, J Martín<sup>1†</sup>, B Rueda<sup>1,10\*†</sup>

From 5th European Workshop on Immune-Mediated Inflammatory Diseases  
Sitges-Barcelona, Spain. 1-3 December 2010

## Introduction

The *TNFSF4* gene, which encodes OX40L, is considered as a potential autoimmunity candidate gene. OX40L is expressed on activated antigen presenting cells (APCs) and endothelial cells in acute inflammation [1]. Furthermore, it enhances B-cell proliferation and differentiation, and its binding to OX40 (CD134) promotes proliferation and survival of T-cells and predisposes them to a more permissive proliferative and survival condition [2]. Interestingly, four *TNFSF4* promoter single-nucleotide polymorphisms (SNP) were recently implicated in susceptibility to systemic sclerosis (SSc) [3].

## Aim

The aim of this study was to confirm the influence of *TNFSF4* polymorphisms on SSc susceptibility and clinical subtypes or phenotypic features.

## Patients and methods

Eight European populations of Caucasian ancestry were included, comprising a total of 3014 SSc patients and 3125 healthy controls. Four genetic variants of the *TNFSF4* gene (rs1234314, rs844644, rs844648 and rs12039904)

were selected as genetic markers and genotyped using Taqman Allelic Discrimination Assays.

## Results

A pooled-analysis revealed the association of rs1234314 and rs12039904 SNPs with SSc [OR=1.15,95%CI 1.02-1.31;OR=1.18,95%CI 1.08-1.29, respectively].

After subtype stratification, significant association of the four tested SNPs with the limited cutaneous SSc (lcSSc) subgroup of patients was revealed [rs1234314 OR=1.22,95%CI 1.07-1.38; rs844644 OR=0.91,95%CI 0.83-0.99; rs844648 OR=1.10,95%CI 1.01-1.20; and rs12039904 OR=1.20,95%CI 1.09-1.33]. Considering autoantibody status, the association of three of these variants, rs1234314, rs844648 and rs12039904 with anticentromere autoantibody (ACA) positive subset of patients remained significant [OR=1.23,95%CI 1.10-1.37; OR=1.12,95%CI 1.01-1.25; OR=1.22,95%CI 1.07-1.38, respectively]. Haplotype analysis confirmed the existence of a previously described protective haplotype and revealed a new risk haplotype with evidence of association with SSc [OR=0.88,95%CI 0.82-0.96;OR=1.14,95%CI 1.03-1.26, respectively], lcSSc [OR=0.88,95%CI 0.80-0.96; OR=1.20,95%CI 1.08-1.35, respectively] and ACA positive subgroups[OR=0.86,95%CI 0.77-0.97;OR=1.23, 95% CI 1.07-1.42, respectively].

† Contributed equally

<sup>1</sup>Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain  
Full list of author information is available at the end of the article

## Conclusions

Our data confirm the influence of *TNFSF4* polymorphisms in SSc genetic susceptibility, especially with lcSSc and ACA positive subsets of patients.

## Author details

<sup>1</sup>Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain. <sup>2</sup>Dept. of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. <sup>3</sup>Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona, Spain. <sup>4</sup>Referral Center for Systemic Autoimmune Diseases, University of Milan, Milan, Italy. <sup>5</sup>Servicio de Medicina Interna, Hospital Clínico Universitario, Granada, Spain. <sup>6</sup>Servicio de Medicina Interna, Hospital Clínico de Barcelona, Barcelona, Spain. <sup>7</sup>Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain. <sup>8</sup>Servicio de Medicina Interna, Hospital Carlos-Haya, Málaga, Spain. <sup>9</sup>Servicio de Medicina Interna, Hospital Virgen de las Nieves, Granada, Spain. <sup>10</sup>Servicio de Inmunología, Hospital Virgen del Rocío, Sevilla, Spain. <sup>11</sup>Servicio de Reumatología, Hospital de la Princesa, Madrid, Spain. <sup>12</sup>Servicio de Reumatología, Hospital Clínico San Carlos, Madrid, Spain. <sup>13</sup>Servicio de Medicina Interna, Hospital Parc Tauli, Sabadell, Spain. <sup>14</sup>Servicio de Reumatología, Hospital del Doctor Peset Aleixandre, Valencia, Spain. <sup>15</sup>Servicio de Reumatología, Hospital Reina Sofía, Córdoba, Spain. <sup>16</sup>Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla, Spain. <sup>17</sup>Servicio de Reumatología, Hospital de Sant Pau, Barcelona, Spain. <sup>18</sup>Servicio de Medicina Interna, Hospital Central de Asturias, Oviedo, Spain. <sup>19</sup>Servicio de Reumatología, Hospital Carlos Haya, Málaga, Spain. <sup>20</sup>Servicio de Medicina Interna, Hospital de Cruces, Barakaldo, Spain. <sup>21</sup>Servicio de Reumatología, Hospital Ramón y Cajal, Madrid, Spain. <sup>22</sup>Servicio de Reumatología, Hospital Del Mar, Barcelona, Spain. <sup>23</sup>Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander, Spain. <sup>24</sup>Dept. of Rheumatology, Lund University Hospital, Lund, Sweden. <sup>25</sup>Dept. of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany. <sup>26</sup>Hannover Medical School, Hannover, Germany. <sup>27</sup>Dept. of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. <sup>28</sup>Section Complex Genetics, Dept. of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. <sup>29</sup>Université catholique de Louvain (UCL), Brussels, Belgium. <sup>30</sup>University of Ghent, Ghent, Belgium. <sup>31</sup>University of Leuven (KULeuven), Leuven, Belgium. <sup>32</sup>Dept. of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands. <sup>33</sup>Dept. of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. <sup>34</sup>University of Glasgow, Glasgow, UK. <sup>35</sup>Centre for Rheumatology, Royal Free and University College Medical School, London, UK. <sup>36</sup>Dept. of Genetics, University of Ghent, Ghent, Belgium. <sup>37</sup>Karolinska Institute, Stockholm, Sweden. <sup>38</sup>Dept. of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. <sup>39</sup>Institute of Immunology, Rikshospitalet, Oslo University Hospital, Oslo, Norway. <sup>40</sup>Servizio di Reumatologia ed Immunologia Clinica Spedali Civili, Brescia, Italy. <sup>41</sup>Institute of Cellular Medicine, Newcastle University, Newcastle, UK. <sup>42</sup>Dept. of Dermatology, University of Cologne, Cologne, Germany. <sup>43</sup>Ruhr University of Bochum, Bochum, Germany. <sup>44</sup>Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Published: 25 November 2010

## References

1. Manku H, Graham DS, Vyse TJ: Association of the co-stimulator OX40L with systemic lupus erythematosus. *J Mol Med*. 2009, **87**:229-234.
2. Gough MJ, Weinberg AD: OX40 (CD134) and OX40L. *Adv Exp Med Biol*. 2009, **647**:94-107.
3. Gourh P, Arnett FC, Tan FK, Assassi S, Divecha D, Paz G, et al: Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. *Ann Rheum Dis*. 2010, **69**:550-555.

doi:10.1186/1479-5876-8-S1-P5

**Cite this article as:** Bossini-Castillo et al.: A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with Systemic Sclerosis in a large European cohort. *Journal of Translational Medicine* 2010 **8**(Suppl 1):P5.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

